The next generation CytoSorb-XL platform enables to remove lipopolysaccharide (LPS) endotoxin, as well as cytokines, exotoxins and other inflammatory mediators.
CytoSorb-XL is said to avoid the need for stand-alone endotoxin specific filters, as it not only removes endotoxin but also a range of inflammatory mediators that may lead to inflammation, organ failure, and death in sepsis.
According to the company, CytoSorb-XL and its novel endotoxin binding chemistry is the subject of a broad composition of matter patent application, intended to protect the technology worldwide for the next two decades.
CytoSorbents CEO Phillip Chan said: "Endotoxin, produced by Gram negative bacteria such as E. coli, is a potent and deadly trigger of severe sepsis and septic shock, but wreaks its havoc through the activation of the immune system and generation of systemic inflammation through cytokine storm.
“This is why endotoxin removal alone is not enough and why the simultaneous removal of endotoxin, cytokines, exotoxins, and other inflammatory mediators is anticipated to be much more efficacious.
“In other words, treatment of sepsis by CytoSorb-XL is expected to be a classic case where one plus one equals three."
The company also produces CytoSorb blood purification cartridge, which is approved in the European Union and distributed in 37 countries across the globe.
CytoSorb will reduce the cytokine storm or cytokine release syndrome, which is expected to cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, and cancer immunotherapy.
Currently, the firm is carrying out reduction in free hemoglobin (REFRESH 1) study to assess the safety of intra-operative CytoSorb use in a heart-lung machine during complex cardiac surgery.
